OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
24 apr 2009 - 07:33
Statutaire naam
OctoPlus N.V.
Titel
OctoPlus' licensee Biolex presents Phase IIa results Locteron at EASL conference
Bericht
OctoPlus N.V. (“OctoPlus” or “the Company”) (Euronext: OCTO) announces today that its licensee Biolex Therapeutics (see separate Biolex press release on www.biolex.com) will present the results from its United States Phase IIa clinical study (the “PLUS” study) with Locteron® today at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) in Copenhagen, Denmark. Results of this study suggest that Locteron may result in less frequent flu-like symptoms when compared to pegylated interferon products.
Datum laatste update: 19 december 2025